Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications

Table 2 Compounds used in clinical trials to treat hepatocellular carcinoma patients

Agent	Targets	Phase	Activity	HCC stage	Ref.
Sorafenib	Raf, MAPK, VEGFR, PDGFRβ	III	Anti-tumor	Advanced	[98]
			Anti-angiogenesis
Cabozanitinib	VEGFR2, KIT, RET, AXL	III	Anti-tumor	Advanced	[99]
Brivanib	FGFR, VEGFR	II	Anti-angiogenesis	Advanced	[100]
Foretinib	FLT1, PDGFRβ, c-Met, VEGFR-2, Tie-2	II	Anti-tumor	Advanced	[101]
	FLT4, RON, FLT3, KIT		Anti-angiogenesis
Everolimus	mTOR	III	Anti-tumor	Advanced	[102]
Cobazitinib	c-Met, VEGFR-2, RET	II	Anti-tumor	Advanced	[103]
			Anti-angiogenesis
Ramucirumab	VEGFR-2	III	Anti-angiogenesis	Advanced	[104]
MSC2156119J	c-Met	Ib/II	Anti-tumor, anti-mestastasis	Advanced	[105]
Gefitinib	EGFR, c-Met, HGF,	II	Anti-tumor	Advanced	[106]
Bevacizumab	VEGFRs	II	Anti-angiogenesis	Advanced	[107]
AZD6244	MEK1/2	Ib	Anti-tumor	Advanced	[108]
AZD4547	p-FGFR-1, p-FGFR-2	I	Anti-tumor, anti-angiogenesis	Advanced	[109]
	p-c-Met,
	p-AKT,
	p-ERK
MK2461	c-Met, Ftl-1	I	Anti-tumor	Advanced	[110]
Crizotinib	p-c-Met	Ib	Anti-angiogenesis	Advanced	[111]
	ALK
Bortezomib	Proteasome inhibitor	II	Anti-tumor	Advanced	[102]
Docetaxel	EGFR	II	Anti-tumor	Advanced
INC280	p-c-Met	II	Anti-tumor	Advanced	[111]

HCC: Hepatocellular carcinoma.